Companies › Meribank Biotech
1 active drug program in 2 registered trials: 1 Phase 2, 1 Phase 1; Other, Respiratory; next expected readout Dec 2026.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| UMC119-06-05 allogeneic umbilical cord mesenchymal stem cells | – | Phase 2 | Chronic Obstructive Pulmonary Disease; Pathologic Processes | Dec 2026 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT06501066 | UMC119-06-05 | Phase 1 | Pathologic Processes | Other | Dec 2026 |
| NCT06491043 | UMC119-06-05 | Phase 2 | Chronic Obstructive Pulmonary Disease | Respiratory | Dec 2026 |
No annotated target.
–
Photozig MaaT Pharma Serum Life Science Europe Distribuidora Biolife SA de CV Circul'Egg
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.